PHAXIAM Therapeutics SA (PHXM)
US29604W2070 - ADR
PHAXIAM Therapeutics SA
NASDAQ:PHXM (3/8/2024, 8:27:22 PM)
After market: 3.1 0 (0%)3.1
-0.02 (-0.64%)
Company Profile
Phaxiam Therapeutics SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
Company Info
PHAXIAM Therapeutics SA
60 avenue Rockefeller
Lyon AUVERGNE-RHONE-ALPES
P: 33478744438
Employees: 49
Website: https://erytech.com/
PHXM News
17 days ago - Phaxiam Therapeutics S.A.PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: Euronext Paris (Market segment C - ISIN Code:...
17 days ago - Phaxiam Therapeutics S.A.PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : Euronext Paris (Compartiment C - Code ISIN : FR001400K4B1 –...
25 days ago - Phaxiam Therapeutics S.A.PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy areaWebinar being held today
25 days ago - Phaxiam Therapeutics S.A.PHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapieTenue d’un webinaire le 27 novembre 2024 « Evolving strategic context for phages, Introducing new opportunities »1 pour présenter la stratégie de PHAXIAM...
a month ago - Phaxiam Therapeutics S.A.PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"a month ago - Phaxiam Therapeutics S.A.PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first
PHXM Twits
Here you can normally see the latest stock twits on PHXM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
